Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation
Sunday, June 2, 2024
6:30 PM – 7:30 PM CT
Please note this live virtual meeting is at: 7:30 PM Eastern; 6:30 PM Central; 5:30 PM Mountain; 4:30 PM Pacific
PROGRAM FEATURES
- Online personalized quality-improvement poster-generation portal
- Downloadable whiteboard animations
FACULTY
Renato G. Martins, MD, MPH Chief, Hematology, Oncology and Palliative Care Professor of Medicine Virginia Commonwealth University Richmond, VA |
|
Balazs Halmos, MD, MS Associate Director for Clinical Science Director, Thoracic Oncology Montefiore Einstein Comprehensive Cancer Center Bronx, NY |
PROGRAM OVERVIEW
This activity will review mechanisms of action of immune checkpoint inhibitors (ICIs), the rationale for their use in combination with chemotherapy to treat metastatic, non-driver-mutated, non-small cell lung cancer (NSCLC), and common immune-related adverse events (irAEs) associated with these agents. This interactive, on-demand experience incorporates didactic presentation, illustrative animations, and case-based discussion. Throughout the program, expert faculty will guide you through relevant clinical trial data and current clinical practice guidelines, while sharing best practices for irAE management and optimal use of frontline ICI-based therapy.
TARGET AUDIENCE
This activity is designed to meet the educational needs of global medical oncologists, oncology nurses, pharmacists, nurse practitioners and other members of the multidisciplinary team in the community setting to maintain an up-to-date understanding of the latest data on immune checkpoint inhibitor regimens in the management of NSCLC.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply clinical trials data from immunotherapy combination regimens in the first-line management of patients with advanced NSCLC
- Evaluate clinical practice guideline recommendations for first-line treatment of individuals with metastatic non-small cell lung cancer without actionable mutations
- Review immunotherapy associated adverse events in patients with advanced NSCLC to enhance their prompt recognition and management
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the live event at [email protected]